DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)

More documents

Recommendations

Info

74 Time for baby talk! Chat to one of Fertility Associates’ fertility experts at Stand 12 and be in to win an iPad! And while you’re there, pick up your free copies of our “Little Details” magazine, our mini Biological Clock and our preconception pregnancy wheel. They are great resources to pass on to your patients. The Cetaphil range provides gentle yet effective cleansing and moisturising for all skin types and is ideal for sensitive, infant and compromised skin. The Gentle Skin Cleanser can be used with or without water, is fragrance free and is proven to be one of the gentlest non-soap cleansers 1 . When it comes to fertility, we understand. www.fertilityassociates.co.nz FAL 031 Available in pharmacies, supermarkets & Farmers stores. www.cetaphil.co.nz Always read the label. Use only as directed. ® Trademark Galderma. For more information call Galderma on: 0800 174 104 (New Zealand). Reference 1: Galderma Data on File. VESICARE is fully funded 1 Come to CSL Biotherapies stand 76-77 to find out more about VESICARE and be in to WIN an Adscope TM 657 valued at over $400. Fully funded for patients with a documented intolerance to oxybutynin. FULLY FUNDED Special authority applies. 1 REFERENCES: 1. PHARMAC funding criteria. VESICARE ® is fully funded under special authority from 1 January <strong>2010</strong>. NAME OF MEDICINE: VESICARE ® contains 5 or 10 mg of solifenacin succinate in a film-coated tablet. INDICATION: VESICARE ® is indicated for the treatment of unstable bladder with symptoms of increased urinary urgency, frequent micturition, and/or urge incontinence. DOSAGE: In adults, the recommended dose is 5mg once daily. If needed, this can be increased to 10mg once daily. Tablets should be swallowed whole. Not recommended for use in children. CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients, Urinary retention, Uncontrolled narrow angle glaucoma, Myasthenia gravis, Severe gastro-intestinal condition (including toxic megacolon), Patients undergoing hemodialysis, Patients with severe hepatic impairment, Patients with severe renal impairment or moderate hepatic impairment and on treatment with a strong CYP3A4 inhibitor. WARNINGS AND PRECAUTIONS: Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with VESICARE ® . If urinary tract infection is present, an appropriate antibacterial therapy should be started, Clinically significant bladder outflow obstruction at risk of urinary retention, Gastrointestinal obstructive disorders, Risk of decreased gastrointestinal motility, Severe renal impairment (doses should not exceed 5 mg for these patients), Moderate hepatic impairment (Child-Pugh score of 7 to 9)( (doses should not exceed 5 mg for these patients), Concomitant use of a strong CYP3A4 inhibitor (doses should not exceed 5 mg for these patients), Pregnancy, Lactation, and may effect ability to drive and use machines. ADVERSE EFFECTS: Dry mouth, Constipation, Nausea, Dyspepsia, Abdominal pain, Blurred vision, Urinary tract infection, Somnolence, Dysgeusia, Dry eyes, Fatigue, Oedema, Difficulty in micturition, Faecal impaction, Colonic obstruction, Urinary retention, Gastro-oesophageal reflux diseases, Dry throat, Vomiting, Cystitis, Dizziness, Headache, Nasal dryness, Dry skin, Pruritus, Rash, Urticaria, and Hallucinations. INTERACTIONS: anticholinergics, metoclopramide, cisapride, ketoconazole, CYP3A4 inhibitors, verapamil, diltiazem, CYP3A4 inducers, rifampicin, phenytoin, carbamazepin. MEDICINE CLASSIFICATION: Prescription Medicine. Please review the full data sheet before prescribing VESICARE ® . Full data sheet is available from CSL Biotherapies (NZ) Ltd, PO Box 62 590, Greenlane, Auckland 1546, www.csl.co.nz, or the Medsafe website www.medsafe.govt.nz Based on VESICARE ® data sheet dated September 2008. VESICARE ® is a registered trademark of Astellas Pharma International. VESI-079-04/11 DA1111PG
Main Programme Main Programme Friday 10th June 2011 75 Hon Tony Ryall Medicopolitical Session - Minister of Health Address Friday, 10 June 2011 Start 11:30am Duration: 20mins Baytrust Forum Notes Mr Grant Robertson Medicopolitical Session - Labour Health Spokeperson Address Friday, 10 June 2011 Start 11:50am Duration: 20mins Baytrust Forum Notes Dr Erica Whineray Kelly Breast Cancer 101 Friday, 10 June 2011 Start 2:00pm Duration: 25mins Baytrust Forum Breast cancer is a leading cause of female cancer related deaths in New Zealand. This will be a brief bullet-point overview covering: risk factors and reasons for our high incidence, current screening and diagnostic guidelines, and the very near future of breast surgery and adjuvant treatment: what’s just on the horizon. Notes 09-12 June 2011 | Energy Events Centre | Rotorua
Page 1 and 2:
www.gpcme.co.nz 09-12 June 2011 | E
Page 3 and 4:
Welcome Welcome again to Rotorua. W
Page 5 and 6:
Contents EXHIBITION SECTION 1 Map o
Page 7 and 8:
Rotorua Map 3 Rotorua Map Useful Co
Page 9 and 10:
Exhibition Listing 5 Exhibitor List
Page 11 and 12:
Companies By Product 7 ADHD 44-46 -
Page 13 and 14:
Prizes & Competitions 9 Tear along
Page 15 and 16:
Prizes & Competitions 11 Exhibitor
Page 17 and 18:
Thursday 09th June 13 Thurs 09th Ju
Page 19 and 20:
Friday 10th June 15 Friday 10th Jun
Page 21 and 22:
Saturday 11th June 17 Saturday 11th
Page 23:
Saturday 12th June 19 Saturday 11th
Page 26 and 27:
22 Caring for the lives of millions
Page 28 and 29: 24 Biographies & Sessions Dr Brian
Page 30 and 31: 26 Biographies & Sessions Dr David
Page 32 and 33: 28 To find out more about visit us
Page 34 and 35: 30 Biographies & Sessions Mr Andrew
Page 36 and 37: 32 Biographies & Sessions Marijke C
Page 38 and 39: 34 Biographies & Sessions Dr Helen
Page 41 and 42: Speakers Biographies Dr Colin Edwar
Page 43 and 44: Biographies & Sessions 39 Speakers
Page 46 and 47: 42 Your osteoporosis patients now h
Page 48 and 49: 44 Biographies & Sessions Dr Paula
Page 50 and 51: 46 Biographies & Sessions Dr Edward
Page 52 and 53: 48 Biographies & Sessions Dr Kevin
Page 54 and 55: 50 Biographies & Sessions Dr Alasda
Page 56 and 57: 52 Biographies & Sessions Mr Grant
Page 58 and 59: 54 Biographies & Sessions Dr Matthi
Page 60 and 61: 56 Biographies & Sessions Dr Tim Su
Page 62 and 63: 58 Ensure you know of all recommend
Page 64 and 65: 60 Pre-Conference Workshop Thursday
Page 68 and 69: 64 Wound Management Casting Needles
Page 74 and 75: 70 CanberraHealth Cooperative Aust
Page 76 and 77: 72 Main Programme Friday 10th June
Page 84 and 85: 80
Page 86 and 87: 82 Clinically proven* to reduce Ins
Page 90 and 91: 86 Practice Managers Programme Frid
Page 92 and 93: 88 Practice Managers Programme Frid
Page 94 and 95: 90 MOVICOL ® macrogol 3350 plus el
Page 96 and 97: 92 Main Programme Saturday 11th Jun
Page 98 and 99: 94 New Zealand’s most prescribed
Page 100 and 101: 96 Main Programme Saturday 11th Jun
Page 102 and 103: 98 The Most Recommended Expectorant
Page 104 and 105: 100 Main Programme Saturday 11th Ju
Page 120 and 121: 116 Healthier Communities through A
Page 122 and 123: 118 Practice Nurses Programme Satur
Page 124 and 125: 120
Page 126 and 127: 122 Main Programme Sunday 12th June
Page 128 and 129:
124 Visit Roche Products at stand 3
Page 130 and 131:
126 Main Programme Sunday 12th June
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
132 Delegate Listings as of 24 May
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
152 GP CME 2012 General Practice Co
Page 158 and 159:
Saturday 11th June 2011 MAIN CONFER
Page 160 and 161:
156 Exhibitor Directory Bayer Healt
Page 162 and 163:
158 Exhibitor Directory DrInfo ....
Page 164 and 165:
160 Exhibitor Directory Johnson & J
Page 166 and 167:
162 Exhibitor Directory New Zealand
Page 168 and 169:
164 Exhibitor Directory Roche Diabe
Page 170 and 171:
166 NO SPECIAL AUTHORITY Help your
Page 172:
168 PLATINUM SPONSOR A Promise for
show all

DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)

Create successful ePaper yourself

Delete template?

Save as template?